Jake Wilkie
Chandler, AZNPI 1942921432
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.9% of the total across 276 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 35 manufacturers, the largest accounting for just 12.7% — the pattern of someone who eats at a lot of different presentations.
Across 276 payments — averaging $19.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$682
- Dexcom, Inc.$676
- BETA Bionics, Inc.$537
- Novo Nordisk$457
- Bayer$380
- Xeris Pharmaceuticals, Inc.$339
- plus $2K from 29 others
What the payments were for
- Food & beverage$5,32699%
- Gifts$591%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 35 | $682 |
| Dexcom, Inc. | 33 | $676 |
| BETA Bionics, Inc. | 45 | $537 |
| Novo Nordisk | 21 | $457 |
| Bayer | 16 | $380 |
| Xeris Pharmaceuticals, Inc. | 17 | $339 |
| Mannkind Corporation | 13 | $267 |
| Corcept Therapeutics | 12 | $249 |
| Boehringer Ingelheim | 10 | $201 |
| Amgen(2 entities) | 9 | $170 |
| Sanofi-aventis U.S. LLC | 7 | $145 |
| Cequr Corporation | 2 | $141 |
| Amneal Pharmaceuticals LLC | 8 | $137 |
| Ascendis Pharma Endocrinology Inc | 4 | $110 |
| AstraZeneca(2 entities) | 5 | $107 |
| Insulet Corporation | 5 | $89 |
| Recordati_rare_diseases_inc. | 4 | $81 |
| Sequel Med Tech, LLC | 2 | $73 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $68 |
| Johnson & Johnson | 3 | $53 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $49 |
| Halozyme Inc | 3 | $47 |
| Ascensia Diabetes Care US Inc. | 2 | $37 |
| Madrigal Pharmaceuticals | 1 | $37 |
| Azurity Pharmaceuticals, Inc. | 2 | $30 |
| Antares Pharma, Inc. | 2 | $30 |
| Kyowa Kirin, Inc. | 1 | $29 |
| Ultragenyx Pharmaceutical Inc. | 1 | $25 |
| Medtronic | 1 | $25 |
| Averitas Pharma Inc. | 1 | $25 |
| Amphastar Pharmaceuticals, Inc. | 1 | $19 |
| Radius Health, Inc. | 1 | $19 |
| Astellas Pharma US Inc | 1 | $17 |
| Ardelyx, Inc. | 1 | $16 |
| Tolmar, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Kerendia$120
- DEXCOM G6 TRANSMITTER$116
- Ozempic$116
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.